Atrás
Rango del Día
$34.20
$34.69
Rango de 52 Semanas
$33.51
$44.89
Volumen
277
Promedio 50D / 200D
$39.52
/
$40.93
Cierre Anterior
$34.24
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Healthcare (626 pares)
| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | 1.3 | 0.4 |
| P/B | 0.6 | 2.9 |
| ROE % | 48.1 | 3.8 |
| Net Margin % | 6.3 | 3.9 |
| Rev Growth 5Y % | 7.6 | 10.0 |
| D/E | 1.0 | 0.2 |
Precio Objetivo de Analistas
No hay cobertura de analistas disponible
Estimaciones de Ganancias
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| FY2027 |
$0.00
$0.00 – $0.00
|
56 B | 0 |
| FY2026 |
$0.00
$0.00 – $0.00
|
52 B | 0 |
Puntos Clave
Revenue grew 7.58% annually over 5 years — modest growth
ROE of 48.10% indicates high profitability
Generating 4.15B in free cash flow
P/E of 1.30 — trading at a low valuation
PEG of 0.43 suggests growth is underpriced
Cash machine — converts 131.53% of earnings into free cash flow
Crecimiento
Revenue Growth (5Y)
7.58%
Revenue (1Y)10.07%
Earnings (1Y)11.23%
FCF Growth (3Y)32.06%
Calidad
Return on Equity
48.10%
ROIC25.22%
Net Margin6.31%
Op. Margin9.12%
Seguridad
Debt / Equity
0.98
Current Ratio1.11
Interest Coverage12.85
Valoración
P/E Ratio
1.30
P/B Ratio0.60
EV/EBITDA1.66
Dividend Yield0.02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 10.07% | Revenue Growth (3Y) | 9.62% |
| Earnings Growth (1Y) | 11.23% | Earnings Growth (3Y) | 11.52% |
| Revenue Growth (5Y) | 7.58% | Earnings Growth (5Y) | 14.47% |
| Profitability | |||
| Revenue (TTM) | 50.01B | Net Income (TTM) | 3.16B |
| ROE | 48.10% | ROA | 14.01% |
| Gross Margin | 25.49% | Operating Margin | 9.12% |
| Net Margin | 6.31% | Free Cash Flow (TTM) | 4.15B |
| ROIC | 25.22% | FCF Growth (3Y) | 32.06% |
| Safety | |||
| Debt / Equity | 0.98 | Current Ratio | 1.11 |
| Interest Coverage | 12.85 | Dividend Yield | 0.02% |
| Valuation | |||
| P/E Ratio | 1.30 | P/B Ratio | 0.60 |
| P/S Ratio | 0.08 | PEG Ratio | 0.43 |
| EV/EBITDA | 1.66 | Dividend Yield | 0.02% |
| Market Cap | 4.09B | Enterprise Value | 7.58B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 50.01B | 45.44B | 41.62B | 39.59B | 37.34B |
| Net Income | 3.16B | 2.84B | 2.54B | 2.64B | 1.84B |
| EPS (Diluted) | 39.32 | 23.84 | 20.84 | 21.60 | 14.88 |
| Gross Profit | 12.75B | 10.63B | 9.31B | 8.43B | 7.27B |
| Operating Income | 4.56B | 4.17B | 3.62B | 3.65B | 2.90B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 22.52B | 20.82B | 19.03B | 17.86B | 17.17B |
| Total Liabilities | 15.69B | 14.53B | 13.07B | 12.17B | 12.37B |
| Shareholders' Equity | 6.84B | 6.29B | 5.96B | 5.70B | 4.81B |
| Total Debt | 6.73B | 3.79B | 3.24B | 3.10B | 2.92B |
| Cash & Equivalents | 3.25B | 2.70B | 2.46B | 2.01B | 2.21B |
| Current Assets | 14.20B | 12.89B | 11.83B | 11.37B | 11.24B |
| Current Liabilities | 12.77B | 11.83B | 10.80B | 9.93B | 10.20B |
Puntuaciones de Estrategias
This stock passed the criteria for 3 strategies
Score = fit strength (0–100)
Rank = position among all matches
Actividad Reciente
Entró
Cash Flow Compounder
Mar 24, 2026
Entró
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entró
Contrarian Investing (David Dreman)
Mar 24, 2026